3-N,N-bis (2-chloroethylamino) p-toluic acid, a new cytostatic drug active in cancer
Dobre, V.; Maltezeanu, G.
Cancer ChemoTherapy Reports 54(5): 319-323
1970
ISSN/ISBN: 0069-0112 PMID: 5514620 Document Number: 23064
Document emailed within 1 workday
Related Documents
Shumkova, E.S.; Solianikova, I.P.; Plotnikova, E.G.; Golovleva, L.A. 2009: Biotransformation of p-toluic acid by bacterium Rhodococcus ruber P25 Mikrobiologiia 78(3): 421-423Svennevig, J.L.; Wennberg, J.E.; Bernstein, O.; Lange, J. 1975: Cytostatic drug combinations in the treatment of metastatic cancer of the breast Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 95(32): 1854-1855; 1866
Kudela, M.; Podivínský, R. 1979: Estimation of the uric acid concentration in the blood-serum during cytostatic therapy of ovarian cancer Ceskoslovenska Gynekologie 44(4): 282-284
Sauer, H. 1991: Cytostatic agents. 2: Cytostatically active antimetabolites Fortschritte der Medizin 109(27): 545-546
Deprez-de Campeneere, D.; Masquelier, M.; Baurain, R.; Trouet, A. 1982: Drug targeting in cancer treatment: active daunorubicin-protein conjugates Progress in Clinical and Biological Research 102 Pt A: 291-298
Cohen, P.R. 2015: Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid Dermatology Online Journal 21(8)
Takada, K.; Shibata, H.; Yamamoto, M. 1981: A cytochemical study of T, active T, non active T and B lymphocytes in respect to acid phosphatase and beta-glucuronidase activity Rinsho Byori. Japanese Journal of Clinical Pathology 29(2): 183-186
Michaelis, M.; Doerr, H.W.; Cinatl, J. 2007: Valproic acid as anti-cancer drug Current Pharmaceutical Design 13(33): 3378-3393
Senning, A.; Buchholt, H.C.; Bierling, R. 1976: Novel Bis-sulfonic Acid Esters with Cytostatic Activity Arzneimittel-Forschung 26(10): 1800-1809
Singwi, M.S.; Lall, S.B. 1980: Cytostatic and cytotoxic effects of flower extract of Hibiscus rosa sinensis on spermatogenically and androgenically active testes of a non-scrotal bat Rhinopoma kinneari Wroughton Indian Journal of Experimental Biology 18(12): 1405-1407
Hambsch, K.; Fischer, H. 1984: Drug side effects in antineoplastic and immunosuppressive cytostatic therapy Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 39(1): 7-14
Kuhlmann, J. 1982: Inhibition of digoxin absorption but not of digitoxin during cytostatic drug therapy Arzneimittel-Forschung 32(6): 698-704
Grabarczyk, H.; Drozdz, B.; Hladoń, B.; Wojciechowska, J. 1977: Sesquiterpene lactones. Part XV. new cytostatic active sesquiterpene lactone from herb of Anthemis nobilis L Polish Journal of Pharmacology and Pharmacy 29(4): 419-423
Reymann, A.; Bunge, A.; Läer, S.; Dietel, M. 1996: Morphological and functional features of cytostatic drug resistance and the effects of MDR modulators Die Pharmazie 51(3): 171-176
Medina, D. 1977: Enhancement of mammary tumor formation in mice by a cytostatic drug, melphalan Cancer Research 37(1): 317-319
Bauer, F.P.; Westhofen, M. 1992: Vestibulotoxic effects of the cytostatic drug carboplatin in patients with head and neck tumors Hno 40(1): 19-24
Blower, P.R. 1990: The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis European Journal of Cancer 26(Suppl 1): S8-11
Joss, R.A.; Brand, B.C.; Buser, K.S.; Cerny, T. 1990: The symptomatic control of cytostatic drug-induced emesis. a recent history and review European Journal of Cancer 26(Suppl 1): S2-S8
Phillips, D.R.; White, R.J.; Trist, H.; Cullinane, C.; Dean, D.; Crothers, D.M. 1990: New insight into drug-DNA interactions at individual drug binding sites probed by RNA polymerase during active transcription of the DNA Anti-Cancer Drug Design 5(1): 21-29
Schenk, P.; Nuhn, P.; Fichtner, I.; Arndt, D. 1990: Studies on sucrose-palmitate-stearate-containing vesicles encapsulating the cytostatic drug methylglyoxal-bis-guanyl-hydrazone Die Pharmazie 45(10): 747-749